Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
Artiva Biotherapeutics (NASDAQ: ARTV), a clinical-stage biotech company focused on developing cell therapies for autoimmune diseases and cancers, announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management will engage in a fireside chat on June 4, 2025, at 9:20 a.m. EDT. The presentation will be accessible via live webcast through the company's investor relations website, with a replay available for 90 days afterward. Additionally, the management team will be available for meetings with registered conference attendees.
Artiva Biotherapeutics (NASDAQ: ARTV), una società biotecnologica in fase clinica specializzata nello sviluppo di terapie cellulari per malattie autoimmuni e tumori, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. Il management dell'azienda parteciperà a una tavola rotonda il 4 giugno 2025, alle 9:20 EDT. La presentazione sarà disponibile in diretta streaming sul sito web delle relazioni con gli investitori della società, con una replica fruibile per 90 giorni successivi. Inoltre, il team dirigenziale sarà disponibile per incontri con i partecipanti registrati alla conferenza.
Artiva Biotherapeutics (NASDAQ: ARTV), una empresa biotecnológica en fase clínica centrada en el desarrollo de terapias celulares para enfermedades autoinmunes y cánceres, anunció su participación en la próxima Jefferies Global Healthcare Conference. La dirección de la empresa participará en una charla informal el 4 de junio de 2025 a las 9:20 a.m. EDT. La presentación será accesible mediante una transmisión en vivo a través del sitio web de relaciones con inversores de la compañía, con una repetición disponible durante 90 días después. Además, el equipo directivo estará disponible para reuniones con los asistentes registrados a la conferencia.
Artiva Biotherapeutics (NASDAQ: ARTV)는 자가면역 질환 및 암 치료를 위한 세포 치료제 개발에 중점을 둔 임상 단계의 바이오테크 기업으로, 다가오는 Jefferies Global Healthcare Conference에 참여한다고 발표했습니다. 회사 경영진은 2025년 6월 4일 오전 9시 20분 EDT에 진행되는 파이어사이드 채팅에 참석할 예정입니다. 발표는 회사 투자자 관계 웹사이트를 통해 라이브 웹캐스트로 시청할 수 있으며, 이후 90일 동안 다시보기 서비스도 제공됩니다. 또한 경영진은 등록된 컨퍼런스 참석자들과의 미팅도 진행할 예정입니다.
Artiva Biotherapeutics (NASDAQ : ARTV), une société biotechnologique en phase clinique spécialisée dans le développement de thérapies cellulaires pour les maladies auto-immunes et les cancers, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. La direction de l'entreprise participera à une discussion informelle le 4 juin 2025 à 9h20 EDT. La présentation sera accessible en webdiffusion en direct via le site des relations investisseurs de la société, avec un replay disponible pendant 90 jours. De plus, l'équipe de direction sera disponible pour des rencontres avec les participants inscrits à la conférence.
Artiva Biotherapeutics (NASDAQ: ARTV), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Zelltherapien für Autoimmunerkrankungen und Krebs spezialisiert hat, gab seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference bekannt. Das Management des Unternehmens wird am 4. Juni 2025 um 9:20 Uhr EDT an einem Fireside Chat teilnehmen. Die Präsentation ist über einen Live-Webcast auf der Investor-Relations-Website des Unternehmens zugänglich, mit einer Wiederholung, die 90 Tage lang verfügbar sein wird. Zudem steht das Management-Team für Treffen mit registrierten Konferenzteilnehmern zur Verfügung.
- None.
- None.
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. EDT.
Members of the Artiva management team will also be available to participate in investor meetings with investors who are registered to attend the conference.
Investors and the general public are invited to listen to a live webcast of the presentation through the "Investors" section on Artivabio.com. A webcast replay will be made available following the event for 90 days.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases. This includes two company-sponsored trials, one in systemic lupus erythematosus for patients with or without lupus nephritis, and a basket trial across autoimmune diseases including rheumatoid arthritis and Sjögren’s disease, as well as an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding upcoming events or Artiva Biotherapeutics, Inc.’s (the “Company”) participation at such events. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investors: Neha Krishnamohan, Artiva Biotherapeutics, ir@artivabio.com
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091
Source: Artiva Biotherapeutics, Inc.
FAQ
When is Artiva Biotherapeutics (ARTV) presenting at the Jefferies Healthcare Conference 2025?
How can investors watch Artiva Biotherapeutics' (ARTV) Jefferies conference presentation?
What is Artiva Biotherapeutics' (ARTV) main focus as a company?
Will Artiva Biotherapeutics (ARTV) management be available for investor meetings at the Jefferies conference?
